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Abstract
Background: While	 treatment	 for	 atopic	 rhinitis	 is	 aimed	mostly	 to	 relieve	 symp‐
toms,	only	allergen‐specific	 immunotherapy	(AIT)	 is	targeted	to	modify	the	natural	
history	of	 allergic	diseases.	This	 results	 in	 sustained	 clinical	 tolerance,	 even	when	
treatment	has	stopped.	The	immunomodulatory	effects	of	AIT	are	attributed	mainly	
to	increased	regulatory	T‐cell	function	and	increased	allergen‐specific	IgG4,	yet	little	
is	known	about	the	effect	on	the	memory	B‐cell	compartment.
Objective: We	aimed	to	examine	the	effects	of	AIT	on	the	IgE‐	and	IgG	subclass‐ex‐
pressing	memory	B	cells.
Methods: We	recruited	29	patients	with	atopic	seasonal	rhinoconjunctivitis	and	per‐
formed	a	longitudinal	analysis	of	the	peripheral	 immune	compartment	before,	dur‐
ing,	and	after	sublingual	immunotherapy	(SLIT)	for	allergy	to	temperate	grass	pollen,	
predominantly	 to	 ryegrass	 pollen	 (RGP;	 Lolium perenne).	 Using	 flow	 cytometry	 on	
peripheral	blood	mononuclear	cells	and	serum	immunoassays,	we	analyzed	the	ef‐
fects	of	a	4	months	preseasonal	treatment	regimen	comprising	two	or	three	courses	
in	consecutive	years	on	circulating	IgE+	and	IgG+	memory	B	cells	and	allergen‐specific	
Ig	levels.
Results: SLIT	 increased	RGP‐specific	serum	IgG2	and	 IgG4,	as	well	as	the	frequen‐
cies	of	IgG2
+	and	IgG4
+	memory	B	cells,	whereas	no	effect	was	observed	on	the	IgE+ 
memory	B‐cell	compartment.	Furthermore,	SLIT	enhanced	proportions	of	regulatory	
T	cells	specific	to	RGP.	These	changes	were	associated	with	clinical	improvement.
Conclusion: Our	data	provide	evidence	for	immunological	effects	of	SLIT	on	B‐cell	
memory.	Skewing	responses	toward	IgG2	and	IgG4	subclasses	might	be	a	mechanism	
to	suppress	IgE‐mediated	allergic	responses.
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1  | INTRODUC TION
Rhinoconjunctivitis	and	other	IgE‐mediated	allergies	are	an	increas‐
ing	 disease	 burden	 globally.1	 Most	 therapies	 for	 allergies	 are	 di‐
rected	at	relieving	symptoms,	but	allergen‐specific	immunotherapy	
(AIT)	 is	 the	only	current	 therapy	 that	modifies	 the	natural	course	
of	 allergic	 diseases.	 Subcutaneous	 immunotherapy	 (SCIT)	 and	
sublingual	 immunotherapy	 (SLIT)	 are	both	proven	effective	 treat‐
ments	 for	 grass	 pollen‐induced	 rhinoconjunctivitis.2‐4	 The	 thera‐
peutic	effect	is	maintained	beyond	the	conclusion	of	treatment.5‐7 
In	patients	with	allergic	rhinitis,	AIT	can	prevent	the	onset	of	new	
sensitizations8	and	decrease	the	likelihood	of	developing	asthma.9 
The	immunomodulatory	properties	of	AIT	affect	local	and	systemic	
immune	 responses,	 with	 an	 impact	 on	 the	 number	 and	 function	
of	 mast	 cells,	 basophils,	 antigen‐presenting	 cells,	 T	 cells,	 and	 B	
cells.10,11
Allergic	 patients	 manifest	 sensitization	 by	 means	 of	 allergen‐
specific	 IgE	 bound	 to	 effector	 cells,	 particularly	 mast	 cells	 and	
basophils.12	 The	 underlying	mechanism	 is	 thought	 to	 be	 a	 shifted	
T‐cell	balance	toward	a	T	helper	2	(Th2)	phenotype,	and	these	cells	
produce	 interleukin	 (IL)‐4	 and	 IL‐13	 that	 direct	 allergen‐specific	 B	
cells	 to	 produce	 IgE.13	 Furthermore,	 Th2	 cells	 produce	 IL‐5	which	
promotes	the	involvement	of	eosinophils	in	the	pathogenesis	of	al‐
lergic	diseases.14	In	contrast,	Th1	responses	are	promoted	by	IFN‐γ 
and	skew	away	from	a	Th2	phenotype.15	Effective	immunotherapy	
has	been	shown	to	reverse	the	Th2	dominance	and	to	result	in	an‐
ergy	of	allergen‐specific	T	cells,16,17	 induction	of	regulatory	T	cells	
(Treg),18‐21	and	production	of	blocking	antibodies	of	the	IgG	and	IgA	
isotypes.22,23	Specifically,	TGF‐β	and	IL‐10	produced	by	Treg	are	piv‐
otal	for	the	successful	immune	deviation	in	AIT.24,25
The	tolerogenic	functions	of	IL‐10	are	extensive,	but	mainly	en‐
compass	 the	 inhibition	 of	 mast	 cell	 activity,26	 suppression	 of	 IL‐5	
production	by	Th2	cells,27	and	cell	death	induction	in	eosinophils.28 
Furthermore,	IL‐10	in	combination	with	IL‐4	and	IL‐13	directs	B‐cell	
immunoglobulin	class	switching	to	IgG4	instead	of	IgE.
29	Indeed,	one	
of	the	known	effects	of	AIT	is	an	increase	in	allergen‐specific	serum	
IgG4	and	an	increased	serum	IgG4/IgE	antibody	ratio	that	is	associ‐
ated	with	clinical	efficacy.30
SCIT	and	SLIT	have	distinct	immunomodulatory	capabilities	that	
appear	related	to	the	different	routes	of	administration.	Sublingual	
administration	results	in	fewer	systemic	adverse	effects,	but	some	
studies	 indicate	 diminished	 clinical	 and	 immunological	 efficacy	
compared	with	subcutaneous	administration.2,31	SLIT	results	 in	 in‐
creased	numbers	of	FoxP3+	Treg	both	in	the	oral	epithelium	and	in	
the	peripheral	blood.23,32	Further	systemic	alterations	are	more	di‐
verse.	Some	studies	report	an	initial	increase	in	allergen‐specific	IgE	
serum	levels,	followed	by	a	decrease	after	1	month.33	Furthermore,	
allergen‐specific	IgG2,	IgG4,	and	IgA	serum	levels	are	reported	to	in‐
crease	in	as	little	as	1	day	after	the	start	of	therapy.33‐35	However,	
other	 studies	 detected	 no	 systemic	 alterations	 with	 regard	 to	
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allergen‐specific	 lymphoproliferation,	 cytokine	 secretion,	 or	 Ig	
serum	levels.36,37
IgG2	 and	 IgG4	 heavy	 chain	 constant	 regions	 are	 encoded	 by	
genes	 in	 the	 IGH	 locus.	 Ig	 class	 switching	 to	 IgG2	 and	 IgG4	 fre‐
quently	occurs	indirectly	following	a	switch	from	IgM	to	the	more	
proximal	IgG3	and	IgG1	genes	rather	than	directly	from	IgM	to	IgG2 
or	IgG4.
38	Given	the	higher	loads	of	somatic	hypermutation	(SHM)	
in	variable	 regions	of	 IgG2	 and	 IgG4	 transcripts,	 it	has	been	sug‐
gested	that	B	cells	expressing	these	transcripts	have	spent	more	
time	 in	 the	germinal	 center	 response.39	 In	addition,	 the	majority	
of	 IgG2‐	 and	 IgG4‐expressing	B	 cells	 co‐express	CD27,	 and	 their	
frequencies	 increase	with	 age.40,41	 Hence,	 it	 appears	 that	 these	
Ig	class	switches	occur	following	repeated	exposure	to	the	same	
antigen.
Since	AIT	has	been	 shown	 to	have	 long‐lasting	beneficial	 ef‐
fects,	 it	 is	 important	 to	 determine	 whether	 this	 is	 the	 result	 of	
changes	in	immunological	memory.	We	here	address	this	question	
in	our	cohort	of	patients	with	moderate‐to‐severe	seasonal	aller‐
gic	 rhinitis,	 studied	 longitudinally	 before,	 during,	 and	 after	 SLIT	
for	grass	pollen	allergy.42	As	published	previously,42,43	SLIT	in	our	
cohort	 resulted	 in	 allergic	 rhinitis	 symptom	 relief	 and	 conferred	
significant	protection	from	epidemic	thunderstorm	asthma,	mak‐
ing	this	an	ideal	cohort	to	examine	the	effects	of	a	4‐month	treat‐
ment	regimen	and	the	subsequent	effects	of	two	further	courses	
of	treatment	over	3	years	on	circulating	IgE+‐	and	IgG	subclass‐ex‐
pressing	memory	B	cells	and	allergen‐specific	Ig	levels.
2  | METHODS
2.1 | Study design
Using	 an	 open‐label	 longitudinal	 design	 (ClinicalTrials.gov	 identifier:	
NCT02014623),	29	participants	were	recruited	for	treatment	with	a	
commercial	5‐grass	pollen	SLIT	tablet	(Oralair®;	Stallergenes)	using	a	
4‐month	(May‐September)	regimen	completed	prior	to	the	Australian	
pollen	season,	for	3	consecutive	years	(2014‐2016;	subject	numbers	at	
each	time	point	shown	in	Figure	1A).	Treatment	with	Oralair® involved 
dissolution	under	the	tongue	(at	least	2	minutes)	followed	by	swallow‐
ing	the	residue.	The	treatment	regimen	comprised	the	following:	day	
1—1	tablet	100	 IR	 (index	of	 reactivity);	day	2—2	tablets	100	 IR;	and	
day	3	to	day	120—1	daily	tablet	300	IR.	Blood	samples	were	collected	
immediately	 before	 initial	 treatment	 (May	 2014)	 and	 after	 the	 first	
4	months	of	treatment	(September	2014),	followed	by	annual	collec‐
tions	in	May	2015	and	May	2016	(prior	to	commencement	of	2nd	and	
3rd	courses	of	SLIT),	and	May	2017	(Figure	1A).
2.2 | Participant characteristics
Participants	 were	 recruited	 from	 The	 Alfred	 Hospital	 Allergy	
Clinic,	 Melbourne,	 Victoria,	 Australia.	 All	 had	 well‐character‐
ized	moderate‐to‐severe	 seasonal	 allergic	 rhinitis	 (plus	or	minus	
asthma)	 due	 to	 RGP	 allergy	 with	 positive	 serum	 RGP‐specific	
IgE	 (≥0.35	 kU/L;	 ImmunoCAP,	 Phadia).	 Exclusion	 criteria	were	 a	
F I G U R E  1  Study	design	and	clinical	parameters	of	allergic	rhinitis	decreased	after	SLIT.	A,	Timeline	of	SLIT	for	grass	pollen	allergy	
between	May	2014	and	2017.	Time	points	indicate	blood	sampling.	B,	Allergic	rhinitis	symptoms	by	visual	analog	scale	measured	during	
peak	pollen	season.	C,	Wheal	diameter	(in	mm)	from	skin	prick	test	(SPT)	with	RGP.	D,	Fractional	exhaled	nitric	oxide	(FeNO)	measured	
immediately	prior	to	starting	SLIT.	E,	Total	IgE	in	serum.	Each	dot	represents	one	individual;	red	lines	indicate	median	values.	Statistical	
analysis	was	performed	between	baseline	and	each	follow‐up	time	point	to	assess	changes	induced	by	SLIT	using	the	Wilcoxon	signed‐rank	
test;	*P	<	.05,	**P	<	.01,	and	***P < .001
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co‐existing	 immunodeficiency,	 previous	 immunotherapy	 within	
the	last	5	years,	ongoing	immunotherapy	with	other	allergens,	and	
treatment	 with	 continuous	 oral	 corticosteroids	 and/or	 β‐block‐
ers.	The	use	of	usual	medications	for	allergic	rhinitis	was	permit‐
ted,	 including	 antihistamines	 and	 topical	 corticosteroids.	 Alfred	
Hospital	 Research	 and	 Ethics	 Committee	 approval	 and	 written	
informed	 consent	 from	 each	 participant	were	 obtained	 prior	 to	
inclusion	 (project	 number	514/13).	 Twenty‐nine	participants	 (12	
males)	were	recruited	for	treatment,	with	a	mean	age	of	35	years	
(range	18‐59	year)	and	mean	serum	RGP‐specific	IgE	of	52	kU/L.	
Five	withdrew	after	 the	 first	 (baseline)	 time	point	 (n	=	4	 tongue	
swelling,	upset	stomach;	n	=	1	failed	to	attend)	leaving	24	partici‐
pants	who	commenced	SLIT	(Table	S1).	At	subsequent	time	points,	
three	 participants	 failed	 to	 attend	 after	 4	months	 of	 treatment	
and	a	further	seven	participants	were	excluded	after	1	year	(n	=	2	
opted	to	receive	SCIT,	n	=	2	opted	to	receive	sublingual	drops,	and	
n	 =	 3	withdrew).	 Blood	 samples	 for	 serum	 and	 flow	 cytometric	
analysis	were	 obtained	 from	 n	 =	 24	 patients	 in	May	 2014	 prior	
to	starting	SLIT,	n	=	24	in	September	2014,	n	=	21	in	May	2015,	
n	=	14	 in	May	2016,	and	n	=	14	 in	May	2017.	Details	on	sample	
numbers	 for	 each	 analysis	 are	 included	 in	Table	 S2.	A	 further	5	
RGP‐allergic	subjects	who	did	not	receive	SLIT	(ie,	received	usual	
medication	alone)	were	included	as	untreated	patients	at	baseline	
and	4	months.
2.3 | Clinical parameters of allergic rhinitis
Allergic	 rhinitis	 symptoms	 during	 the	 peak	 RGP	 season	 were	 re‐
corded	by	the	participants	using	a	visual	analog	score	 (VAS;	scale,	
0‐100).	 Fractional	 exhaled	 nitric	 oxide	 (FeNO,	 in	 parts	 per	 billion	
[ppb];	HypoAirFeNO)	was	measured	according	 to	 the	manufactur‐
er's	instructions	(NIOX,	Uppsala,	Sweden).	FeNO	was	measured	im‐
mediately	before	the	start	of	SLIT	therapy	outside	of	the	grass	pollen	
season	to	minimize	effects	of	daily	fluctuations	in	pollen	levels.
2.4 | Quantification of serum total IgE and allergen‐
specific IgE, IgG2, and IgG4
Serum	total	IgE,	RGP‐specific‐IgE,	and	‐IgG4	levels	were	measured	
by	ImmunoCAP.	Serum	RGP‐specific	 IgG2	antibodies	were	meas‐
ured	by	 in‐house	ELISA,	as	described	previously.44	Briefly,	ELISA	
plate	wells	were	coated	with	an	aqueous	RGP	extract	(Stallergenes	
Greer),	 blocked	 with	 2%	 bovine	 serum	 albumin	 in	 PBS	 (Sigma‐
Aldrich),	 and	 incubated	 with	 serial	 dilutions	 of	 serum	 samples.	
Separate	wells	were	coated	with	serial	dilutions	of	purified	human	
IgG2	 (Sigma‐Aldrich,	 #I5404)	 to	 generate	 a	 standard	 curve	 for	
quantification	of	IgG2	in	serum	samples.	Bound	IgG2	was	detected	
using	 biotinylated	 anti‐hIgG2	 (clone	 HP6002;	 Thermo	 Scientific)	
followed	 by	 Pierce	 High	 Sensitivity	 Streptavidin‐HRP	 (Thermo	
Scientific).	 ELISA	was	 developed	 using	 TMB	 (Thermo	 Scientific),	
and	 the	 reaction	 stopped	 with	 1	 mol/L	 HCl.	 Absorbance	 (OD	
450	 nm)	 was	 measured	 using	 a	 FLUOstar	 Optima	 plate	 reader	
(BMG	Labtech).
2.5 | In vitro RGP stimulation of PBMC, Treg 
staining, and measurement of cytokines
PBMC	were	 isolated	by	Ficoll‐paque	density	 centrifugation.	 Fresh	
PBMC	were	used	for	in	vitro	culture,	and	the	remaining	cells	stored	in	
liquid	nitrogen.	PBMC	were	labeled	with	CFSE	(0.5	µmol/L	CFSE/107 
PBMC;	Molecular	Probes)	and	cultured	with	an	aqueous	RGP	extract	
(50 μg/mL;	Stallergenes	Greer)	or	tetanus	toxoid	(20	Lfu/mL;	Statens	
Serum	Institut,	Copenhagen,	Denmark).	On	day	7,	cells	were	stained	
with	CD4‐PE	Cy7,	CD25‐PE	(both	from	BD	Biosciences),	FoxP3‐APC	
(eBioscience),	and	aqua	live/dead	dye	(Life	Technologies).	The	Treg	
gating	strategy	is	shown	in	Figure	S1.	Data	were	acquired	using	an	
LSR‐II	flow	cytometer	(BD	Biosciences).
The	 levels	 of	 IFN‐γ,	 IL‐5,	 IL‐10,	 and	 IL‐13	 in	 7‐day	 culture	 su‐
pernatants	 were	 determined	 using	 a	 Luminex	 human	 premixed	
multi‐analyte	 kit	 (R&D	 Systems	 Inc)	 according	 to	 the	manufactur‐
er's	instructions.	Due	to	changes	in	IL‐5	production	observed	after	
3	years	of	SLIT,	 IL‐13	was	also	assessed	at	 the	same	time	point	 to	
further	investigate	Th2	cytokine	production.	Tetanus	toxoid	was	in‐
cluded	as	a	control	antigen	to	determine	RGP	specificity.	“No	anti‐
gen”	values	were	subtracted	from	test	values.
2.6 | B‐cell subset analysis by flow cytometry
One	million	thawed	PBMC	were	incubated	with	11‐color	antibody	
cocktails	against	B‐cell	markers	for	15	minutes	at	room	tempera‐
ture	 in	100	µL	 total	volume	 (Table	S3).	Flow	cytometric	analyses	
were	 performed	 on	 a	 4‐laser	 LSRFortessa	 (BD	 Biosciences),	 and	
data	were	analyzed	using	FACSDiva	V8.0	(BD	Biosciences).	B‐cell	
subsets	were	defined	as	described	previously.41,45,46	Briefly,	within	
the	 CD19+	 B‐cell	 population,	 the	 proportions	 were	 determined	
of	 plasmablasts	 (CD27+CD38high),	 transitional	 (CD27−CD38high),	
naive	 mature	 (CD27−IgM+IgD+),	 natural	 effector	 memory	 B	 cells	
(CD27+IgM+IgD+),	and	IgM‐only	memory	B	cells	 (CD27+IgM+IgD–).	
Furthermore,	 we	 analyzed	 Ig	 switched	 CD27−CD38dim and 
CD27+CD38dim	memory	B	cells	expressing	IgA,	IgE,	IgG,	or	each	of	
the	4	IgG	subclasses.
2.7 | Molecular analysis of Ig gene rearrangements
RNA	was	 isolated	 from	 PBMC	 from	 a	 limited	 cohort	 of	 5	 subjects	
treated	with	SLIT	 (Table	EI;	patient	no.	1,	11,	13,	15,	and	19)	with	a	
GenElute	mammalian	RNA	kit	(Sigma‐Aldrich)	and	reverse	transcribed	
to	cDNA	with	random	primers	(Invitrogen	Life	Technologies,	Waltham,	
MA).	 Rearranged	 IgG	 transcripts	were	 amplified	 in	 a	multiplex	 PCR	
approach	 using	 4	 different	 IGHV	 family	 leader	 forward	 primers	 in	
combination	with	an	IGHG‐consensus	reverse	primer.47	PCR	products	
were	cloned	into	a	pGEMT	easy	vector	(Promega),	amplified	by	colony	
PCR,	and	sequenced	by	the	Micromon	facility	of	Monash	University	
on	an	Applied	Biosystems	3730s	DNA	Analyzer	 (Thermo	Scientific).	
Obtained	sequences	were	analyzed	using	the	IMGT	database	(http://
www.imgt.org)	to	assign	the	IGHV,	IGHD, and IGHJ	gene	alleles	and	to	
identify	SHM.	For	each	unique	clone,	 the	position	and	frequency	of	
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mutations	were	determined	within	the	entire	IGHV	gene	(FR1‐CDR1‐
FR2‐CDR2‐FR3).	 SHM	 was	 determined	 as	 variations	 on	 the	 best‐
matched	V‐gene	and	represented	as	the	percentage	of	mutations	of	
the	total	sequenced	V‐gene	nucleotides.	The	IgG	subclasses	were	de‐
termined	using	the	IGH	reference	sequence	(NG_001019).
2.8 | Statistical analysis
Differences	in	symptom	scores,	serum	Ig	values,	cytokines,	and	B‐	and	
T‐cell	subsets	before,	during,	and	after	treatment	were	analyzed	with	
the	Wilcoxon	signed‐rank	test.	All	analyses	were	two‐tailed,	and	dif‐
ferences	were	considered	statistically	significant	if	P‐values	were	<.05.	
Due	to	missing	values	at	year	1,	2,	and	3	measures,	it	was	not	possible	
to	use	repeated	measures	ANOVA.	Therefore,	we	performed	pairwise	
analysis	between	time	point	0	and	each	follow‐up	sample.	Differences	
in	IgG	subclass	usage	of	unique	IGH	transcripts	were	statistically	ana‐
lyzed	 with	 the	 chi‐squared	 test.	 Statistical	 analysis	 was	 performed	
using	GraphPad	Prism	software,	version	7.01	(GraphPad	Software).
3  | RESULTS
3.1 | SLIT reduces symptoms of allergic rhinitis
To	 study	 the	 clinical	 effects	 of	 SLIT,	 we	 assessed	 the	 severity	 of	
symptoms	for	allergic	rhinitis	using	a	VAS.	Before	the	start	of	treat‐
ment,	participants	reported	a	median	VAS	of	80	mm	for	 the	2013	
pollen	 season	 (Figure	 1B).	 In	 the	 first	 pollen	 season	 after	 com‐
mencing	 SLIT,	 participants	 experienced	 fewer	 symptoms	 (median	
VAS	40	mm,	P	<	.001),	and	these	remained	low	for	the	second	and	
third	seasons	following	repeat	SLIT	courses	(median	VAS	20	mm	at	
2	years,	P	<	.001;	median	VAS	35	mm	at	3	years,	P	<	.01),	confirming	
sustained	clinical	efficacy.
The	 level	 of	 RGP	 sensitization	 was	 monitored	 by	 skin	 prick	
tests	(SPT)	with	wheal	diameters	(mm)	positively	correlating	with	
symptoms	of	 allergic	disease.48	 SLIT	 significantly	decreased	SPT	
wheal	diameter	in	response	to	SPT	with	RGP	extract	within	1	year	
of	 commencing	 therapy	 (Figure	 1C).	 Wheal	 size	 remained	 low	
on	 retesting	 after	 the	 third	 year	 of	 SLIT.	 In	 addition,	 the	 sever‐
ity	of	airway	 inflammation	and	bronchial	hyperreactivity	was	as‐
sessed	by	measurement	of	FeNO.49,50	SLIT	significantly	decreased	
FeNO	from	baseline	at	1,	2,	 and	3	years	after	 commencing	SLIT	
(Figure	1D).	The	significant	decreases	in	SPT	wheal	diameter	and	
F I G U R E  2  Sublingual	immunotherapy	(SLIT)	alters	in	vitro	Treg	proliferation	and	cytokine	production	in	response	to	RGP.	PBMC	
stimulated	with	RGP	were	assessed	for	A,	Treg	proliferation	and	production	of	B,	IL‐10,	C,	IFN‐γ,	and	D,	IL‐5	were	determined	for	all	patients	
included	at	t	=	0,	1,	2,	3	y.	E.	Paired	analysis	of	IL‐5	and	F.	IL‐13	at	t	=	0	and	t	=	3	y.	The	lower	limit	of	detection	of	IL‐10	levels	(0.5	pg/mL)	in	
panel	B	is	depicted	by	a	dashed	line	and	datapoints	representing	undetectable	levels	are	placed	below	it.	Statistical	analysis	was	performed	
between	baseline	and	each	follow‐up	time	point	to	assess	changes	induced	by	SLIT	using	the	Wilcoxon	signed‐rank	test;	*P	<	.05,	**P	<	.01,	
***P	<	.001	and	****P < .0001
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F I G U R E  3  RGP‐specific	IgG4	and	IgG4
+:IgE+	memory	B‐cell	ratio	increased	after	a	4‐mo	course	of	SLIT.	A,	Gating	strategy	for	Ig	isotype	
and	IgG	subclass‐expressing	memory	B	cells	by	flow	cytometry.	B,	RGP‐specific	IgG2	and	IgG4	in	sera	and	C,	proportion	of	IgG2
+	and	IgG4
+ 
memory	B	cells	as	a	percentage	of	IgG+	population	after	4	mo	of	SLIT.	D,	Proportion	of	IgE+	memory	B	cells	as	a	percentage	of	total	CD19+	B	
cells	after	4	mo	of	SLIT.	E,	Ratio	of	IgG4
+	to	IgE+	B‐cell	percentages	after	4	mo	of	SLIT	(from	C	and	D).	Each	dot	represents	one	individual;	red	
lines	indicate	median	values.	Statistical	analysis	was	performed	between	baseline	and	each	follow‐up	time	point	to	assess	changes	induced	
by	SLIT	using	the	Wilcoxon	signed‐rank	test.	*P	<	.05	and	****P < .0001
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FeNO	were	consistent	with	decreased	symptoms	of	allergic	rhini‐
tis	1	year	after	commencing	treatment	as	well	as	after	the	second	
and	third	successive	years	of	SLIT.	The	reduction	in	VAS	and	FeNO	
after	SLIT	did	not	correspond	with	any	changes	in	total	serum	IgE	
levels	(Figure	1E).
3.2 | Induction of RGP‐specific Treg and IL‐10 
production following SLIT
Successful	AIT	 has	 been	 associated	with	 proliferation	 of	 allergen‐
specific	Treg.50	To	assess	Treg	proliferation	in	response	to	allergen,	
we	 stimulated	PBMC	with	RGP	and	measured	 the	proliferation	of	
activated	Treg	(CD4+CD25+FoxP3+)	using	CFSE.	RGP‐induced	prolif‐
eration	of	Treg	was	enhanced	by	SLIT	after	4	months	and	remained	
raised	throughout	subsequent	years	(Figure	2A).
Given	the	role	of	cytokines	in	skewing	T‐cell	responses,	we	quan‐
tified	 IL‐5,	 IL‐10,	 IL‐13,	and	 IFN‐γ	production	 from	RGP‐stimulated	
PBMC.	 After	 3	 years	 of	 SLIT,	 T	 cells	 produced	 significantly	more	
IL‐10	 and	 IFN‐γ	 and	 significantly	 less	 IL‐5	 and	 IL‐13	 (Figure	 2B‐E).	
SLIT	 did	 not	 alter	 the	 PBMC	 cytokine	 response	 to	 tetanus	 toxoid	
(Figure	S2).	Taken	together,	the	data	from	our	study	suggest	SLIT	en‐
hances	Treg	response	to	allergen	within	4	months	without	impacting	
the	 Treg	 response	 to	 other	 antigens.	 Furthermore,	 SLIT	may	 alter	
the	Th1/Th2	cytokine	profile	away	from	pro‐allergic	Th2	cytokines	
toward	a	regulatory	and	Th1‐biased	response.
3.3 | Increased IgG4 serum levels and IgG4
+ memory 
B‐cell frequencies after 4 months SLIT
To	 study	 the	 short‐term	 effects	 of	 SLIT	 on	 the	 immune	 system,	
we	analyzed	serum	Ig	levels	and	B‐cell	subsets	before	and	directly	
F I G U R E  4  Persistent	increase	in	IgG4	and	late	rise	in	IgG2	after	three	4‐mo	SLIT	courses.	A,	RGP‐specific	IgE,	IgG2	and	IgG4	in	serum.	B,	
Proportions	of	IgE+,	IgG2
+,	and	IgG4
+	memory	B	cells	in	peripheral	blood.	IgE+	memory	B	cells	presented	as	a	percentage	of	CD19+	B	cells.	
IgG2
+	and	IgG4
+	memory	B	cells	presented	as	a	percentage	of	IgG+	memory	B	cells.	Baseline	data	for	IgE+	and	IgG4+	B	cells	are	the	same	as	
those	in	Figure	3C	and	D.	Statistical	analysis	was	performed	between	baseline	and	each	follow‐up	time	point	to	assess	changes	induced	by	
SLIT	using	the	Wilcoxon	signed‐rank	test;	*P	<	.05	and	**P < .01
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after	 the	 first	 4	 months	 of	 therapy.	 The	 gating	 strategies	 for	
flow	cytometric	detection	of	memory	B	cells	expressing	the	four	
IgG	 subclasses	 are	 shown	 in	 Figure	 3A.	We	 observed	 that	 after	
4	months	of	 immunotherapy,	RGP‐specific	 serum	 IgG2	 increased	
from	a	median	of	2.46	to	5.08	μg/mL	(Figure	3B).	Furthermore,	all	
participants	showed	an	increase	in	RGP‐specific	serum	IgG4	from	a	
median	of	0.37	μg/mL	pretreatment	to	1.16	μg/mL	post‐treatment	
after	4	months	of	SLIT.	This	was	accompanied	by	a	significant	in‐
crease	 in	 the	 frequency	of	 IgG+	memory	B	cells	 (CD19+CD38dim)	
expressing	 IgG4	 (Figure	 3C).	 The	 increase	 in	 the	 IgG4
+ memory 
B‐cell	 frequencies	was	 not	 directly	 correlated	with	 the	 increase	
in	 RGP‐specific	 serum	 IgG4 (p	 >	 .05).	 SLIT	 did	 not	 change	 IgE
+ 
memory	B‐cell	frequencies	(Figure	3D).	However,	the	increase	in	
IgG4
+	memory	B	cells	resulted	in	a	significantly	higher	IgG4
+/IgE+ 
memory	B‐cell	ratio	following	4	months	of	treatment	(Figure	3E).	
The	frequencies	of	all	other	B‐cell	subsets,	including	transitional,	
naive	 mature,	 memory,	 and	 plasmablasts,	 remained	 unchanged	
after	4	months	of	SLIT	(Figure	S3).	Thus,	4	months	SLIT	quite	spe‐
cifically	affected	allergen‐specific	 IgG4	 serum	 levels	and	the	fre‐
quencies	of	IgG4‐expressing	memory	B	cells.
3.4 | SLIT has persistent long‐term effects on 
IgG2 and IgG4 memory B cells
In	addition	to	short‐term	effects	of	SLIT,	we	studied	the	longer‐term	
effects	of	SLIT,	that	 is,	1,	2,	and	3	years	after	the	start	of	the	first	
treatment	course.	SLIT	did	not	significantly	alter	serum	RGP‐specific	
IgE	levels	(Figure	4A).	RGP‐specific	IgG2	levels	increased	after	a	total	
of	3	courses	of	SLIT	(Figure	4A).	RGP‐specific	IgG4	 increased	after	
each	consecutive	course	of	treatment	at	1,	2,	and	3	years	(Figure	4A).	
Similar	to	RGP‐specific	IgE	and	IgG2	antibodies,	frequencies	of	IgE
+ 
memory	 B	 cells	 were	 unchanged	 by	 SLIT,	 while	 IgG2
+	 memory	 B	
cells	 were	 significantly	 increased	 3	 years	 after	 commencing	 SLIT	
(Figure	 4B).	 Frequencies	 of	 IgG4
+	 memory	 B	 cells	 were	 increased	
2	years	after	commencing	SLIT.
3.5 | Molecular analysis of Ig gene rearrangements
Given	that	SLIT	increased	IgG2	and	IgG4	antibodies	and	memory	B‐
cell	 proportions,	we	 investigated	whether	 these	 changes	were	 re‐
flected	 in	 the	proportions	of	 unique	 IgG	 transcripts	 from	blood	B	
cells	for	a	subgroup	of	5	participants	with	an	increased	percentage	
of	IgG2
+	memory	B	cells	after	SLIT.	Median	frequencies	of	somatic	
hypermutations	did	not	differ	 between	 the	proximal	 IgG1	 and	 the	
distal	IgG2	subclasses	(Figure	5A	and	B)	nor	were	significantly	differ‐
ent	after	3	years	SLIT.	However,	after	3	years	SLIT	the	relative	usage	
of	the	IgG2	and	IgG4	subclasses	were	significantly	increased	at	the	
expense	of	IgG1	(Figure	5C).	Taken	together,	these	data	demonstrate	
that	repeat	courses	of	SLIT	for	grass	pollen	allergy	induce	allergen‐
specific	IgG2	and	IgG4	responses,	evidenced	by	an	increase	in	IgG2
+ 
and	 IgG4
+	B‐cell	proportions	and	skewing	toward	unique	 IgG2 and 
IgG4	transcripts.
4  | DISCUSSION
We	 here	 report	 that	 SLIT	 for	 grass	 pollen	 allergy	 not	 only	 has	
long‐term	 beneficial	 clinical	 effects,	 but	 also	 results	 in	 sustained	
systemic	effects	on	 the	 immune	system.	SLIT	 induced	a	 rapid	and	
prolonged	increase	in	RGP‐specific	serum	IgG4	accompanied	by	an	
increase	in	the	frequency	of	peripheral	blood	IgG4
+	memory	B	cells.	
Furthermore,	repeat	courses	of	SLIT	resulted	in	a	similar	increase	in	
RGP‐specific	IgG2	in	serum	corresponding	with	increased	frequency	
of	IgG2
+	memory	B	cells	in	the	blood.
Currently,	grass	pollen	SLIT	is	recommended	as	a	preseasonal	
and	co‐seasonal	 course	starting	4	months	prior	 to	 the	hay	 fever	
season,	 confirmed	 by	meta‐analyses	 as	 clinically	 effective.2	 Yet,	
long‐term	 treatment	 regimens	 are	 costly	 and	 discourage	 treat‐
ment	adherence.51	As	patients	are	exposed	to	grass	pollens	during	
the	spring	season,	we	reasoned	that	a	4	months	preseasonal	treat‐
ment	 regimen	 would	 avoid	 the	 risk	 of	 adding	 to	 excessive	 and	
F I G U R E  5  Sublingual	immunotherapy	(SLIT)	increases	frequency	of	unique	IgG2	transcripts.	A,	Schematics	of	the	human	IGH	locus	
depicting	the	positioning	of	the	constant	gene	regions	relative	to	the	rearranged	VDJ	exon.	B,	Somatic	hypermutation	frequencies	of	unique	
IgG	transcripts	obtained	from	5	patients	before	(2014)	and	after	SLIT	(2017)	and	grouped	per	IgG	subclass.	C,	Relative	isotype	distribution	
of	unique	IgG	transcripts.	Central	number	indicates	total	unique	IgG	sequences	identified.	Significance	was	determined	by	chi‐squared	test;	
**P	=	.0011
IgG2
46.9%
IgG1
52.2%
IgG4
0%
111
IgG2
66.4%
IgG1
31.1%
IgG3
0.8%
IgG4
1.7%
119
pre-SLIT 3 y SLIT
**
IgG3 IgG1 IgG2 IgG4
0
4
8
12
%
 S
H
M
 in
 IG
H
V
n.d.
0 3 y 0 3 y 0 3 y 0 3 y
(n 
= 2
)
(n 
= 1
)
(n 
= 5
8)
(n 
= 3
7)
(n 
= 5
5)
(n 
= 7
7)
(n 
= 3
)
V DJ Cμ Cδ CεΨε ΨγCγ3 Cγ2 Cγ4Cα1 Cα2
Sμ SεSγ3 Sγ1 Sγ2 Sγ4Sα1 Sα2
Cγ1(A)
(B) (C)
IgG3
0.9%
     |  9HEERINGA Et Al.
unpredictable	allergen	loads	during	the	Melbourne	Spring.	Based	
on	our	analysis	of	symptom	scores,	this	approach	is	highly	effec‐
tive.42,43	Prolonged	treatment	(duration	>	12	months)	is	known	to	
have	beneficial	effects	on	symptom	and	medication	scores.52 The 
fact	that	some	immunological	effects	are	delayed,	only	occurring	
after	 the	 second	 or	 third	 treatment	 year	 as	 observed	 for	 serum	
RGP‐specific	 IgG2	 levels,	 or	 continuing	 to	 rise	 after	 consecutive	
treatment	as	 for	 serum	RGP‐specific	 IgG4	 levels,	 supports	 these	
premises.
In	particular,	we	observed	a	marked	 increase	 in	RGP‐specific	
IgG.	 Previously,	 allergen‐specific	 immunotherapy,	 either	 SCIT	 or	
SLIT,	 has	 already	 been	 demonstrated	 to	 result	 in	 increased	 al‐
lergen‐specific	 IgG4	 serum	 levels.
53,54	 Increased	 allergen‐spe‐
cific	IgG4	has	been	postulated	as	one	of	the	explanations	for	the	
beneficial	 effects	 of	 immunotherapy	 and	 has	 been	 observed	 as	
a	 natural	 effect	 in	 beekeepers	 exposed	 to	 bee	 venom	 for	 pro‐
longed	 periods,55	 yet	 the	 exact	 desensitizing	 effect	 of	 specific	
IgG4	 in	 immunotherapy	 remains	 unclear.	 Allergen‐specific	 IgG4 
can	 competitively	 inhibit	 IgE	 from	 binding	 to	 allergens	 and	may	
subsequently	reduce	allergic	responses	by	preventing	FcεR‐medi‐
ated	activation	of	granulocytes.56	Furthermore,	IgG4	antibody	has	
been	 proposed	 to	 inhibit	 inflammatory	 responses	 by	 preventing	
C1q	complement	activation	and	binding	to	the	inhibitory	receptor	
FcγRIIb	(CD32b).57,58
SLIT	 also	 increased	 RGP‐specific	 IgG2	 after	 three	 consecutive	
courses	 of	 SLIT.	 This	 suggests	 repeated	 or	 high‐dose	 exposure	 to	
RGP	from	SLIT	is	required	to	enhance	RGP‐specific	IgG2	beyond	that	
which	is	generated	from	annual	RGP	exposure	during	the	pollen	sea‐
son.	Furthermore,	sublingual	administration	of	RGP	may	have	pref‐
erentially	 induced	 an	 IgG2	 response	 not	 seen	 from	 environmental	
exposure	through	the	airway.
The	 immune	mechanisms	 by	which	 allergen‐specific	 IgG2 may 
contribute	 to	 the	benefits	of	 immunotherapy	 remain	unclear.	 IgG2 
has	been	shown	to	 inhibit	histamine	release	from	basophils	by	ac‐
tivating	FcγRIIb	and	may	reduce	allergic	symptoms	by	this	mecha‐
nism.59	In	a	similar	manner	to	IgG4,	IgG2	may	also	bind	allergen	and	
prevent	effector	cell	degranulation	by	masking	IgE	epitopes.
The	source	of	increased	serum	IgG2	and	IgG4	levels	is	IgG2‐	and	
IgG4‐producing	plasma	cells,	respectively.	As	the	majority	of	serum	
IgG	is	produced	by	bone	marrow	residing	plasma	cells,	we	were	un‐
able	 to	 assess	 these.	However,	we	 did	 assess	 the	more	 immature	
plasmablasts	 in	 blood,	 finding	 that	 their	 frequencies	were	 not	 af‐
fected	by	SLIT.	Further	characterization	of	Ig	isotypes	and	IgG	sub‐
classes	was	not	possible	due	to	our	approach	for	membrane	staining,	
since	the	majority	of	plasmablasts	(especially	those	producing	IgG)	
lack	 surface	 Ig	 expression.	 Hence,	 we	 focused	 on	 the	 analysis	 of	
memory	B	cells,	which	are	abundant	in	the	blood	due	to	their	circu‐
latory	nature,	and	their	capacity	to	quickly	differentiate	into	plasma	
cells	in	subsequent	antigen	responses.60
We	observed	that	SLIT	drives	increased	frequencies	of	IgG2
+ and 
IgG4
+	memory	B	cells,	whereas	there	was	no	effect	on	frequencies	
of	 IgE+	memory	B‐cell	 subsets.	The	 latter	observation	 can	explain	
the	absence	of	a	decline	 in	 IgE	serum	 levels	as	also	demonstrated	
by	others.52,61,62	Since	we	observed	the	 increase	 in	 IgG4
+ memory 
B	cells	after	4	months	of	treatment	with	SLIT,	and	before	the	pollen	
season,	this	effect	can	be	directly	attributed	to	the	treatment	with	
Oralair®.	Our	observation	that	frequencies	of	IgG4
+	memory	B	cells	
remain	increased	for	at	least	3	years	can	be	an	explanation	for	the	
long‐lasting	effects	attributed	to	immunotherapy.5‐7
Allergen‐specific	 IgG2	 and	 IgG4	 appear	 to	 be	 robust	markers	
of	repeated	allergen	exposure.	Increases	in	allergen‐specific	IgG2 
and	IgG4	alongside	increased	frequency	of	IgG2
+	and	IgG4
+ mem‐
ory	B	cells	may	arise	from	class	switching	of	allergen‐specific	IgG1
+ 
memory	 B	 cells	 upon	 repeated	 exposure	 to	 allergen.	 Sequential	
Ig	class	switching	can	only	occur	5’–3’	along	the	IGH	locus,	which	
is	arranged	in	the	following	order:	IgG3	>	IgG1	>	IgG2	>	IgG4	>	Ig
E	>	 IgA	 (Figure	5A).	As	such,	 IgG1
+	B	cells	may	switch	to	 IgG2 or 
IgG4	but	not	vice	versa.	In	a	study	of	allergen‐specific	antibodies	in	
children	from	birth	to	10	years	old,	IgE	responses	to	aeroallergens	
were	typically	preceded	by	IgG.63	Allergen‐specific	IgG+ memory 
B	cells	may	therefore	provide	a	reservoir	for	switching	to	IgE	that	
can	be	 induced	by	repeated	exposure	to	the	allergen	and	subse‐
quently	 cause	 allergic	 sensitization.	 A	 similar	 pathway	may	 give	
rise	to	allergen‐specific	IgG2	and	IgG4,	whereby	allergen	exposure	
promotes	class	switching	of	allergen‐specific	IgG1
+	memory	B	cells	
to	IgG2	and	IgG4.	Switching	to	IgG2	and	IgG4	may	help	explain	why	
many	allergies	subside	with	age,	perhaps	due	to	repeated	allergen	
exposure	throughout	childhood.	However,	it	remains	to	be	deter‐
mined	whether	allergen‐specific	 IgG2	and	 IgG4	are	 indispensable	
for	 generating	 clinical	 benefit	 by	 SLIT	 in	 lieu	 of	 T	 cell–mediated	
tolerance.
In	 line	with	previous	 reports,	we	observed	 that	proliferation	
of	Treg	from	patients	after	SLIT	was	 increased	 in	response	to	 in	
vitro	stimulation	with	RGP.	Previous	studies	have	observed	new	
generation	of	 allergen‐specific	 Treg,	 as	well	 as	 clonal	 expansion	
of	allergen‐specific	Treg	in	response	to	AIT.56,64	Furthermore,	we	
observed	 that	SLIT	 increased	 IL‐10	production	 from	RGP‐stimu‐
lated	 PBMC,	 whereas	 IL‐13	 was	 diminished.	 The	 cytokines	 IL‐4	
and	IL‐13	promote	Ig	class	switch	recombination	(CSR)	to	IgE,	and	
these	are	predominantly	produced	by	Th2	cells.	In	addition	to	Th2	
cytokines,	CSR	to	IgG4	is	also	regulated	by	IL‐10	which	is	predom‐
inantly	 secreted	 by	 Treg.	 Our	 data	 are	 consistent	 with	 SLIT‐in‐
duced	proliferation	of	 allergen‐specific	Treg,	whereby	 increased	
IL‐10	 production	 induces	 Ig	 class	 switching	 of	 allergen‐specific	
B	 cells	 to	 IgG4.	 B	 regulatory	 cells	 (Breg)	 and	monocyte‐derived	
macrophages	may	also	be	an	alternative	source	of	IL‐10	in	our	in	
vitro	assay,	further	enhancing	IgG4	class	switching	in	response	to	
RGP.65,66
In	conclusion,	our	data	provide	evidence	for	long‐lasting	effects	
of	allergen	SLIT	on	the	memory	compartment	of	the	immune	system.	
Increased	Treg	frequencies	and	increased	IL‐10	production	were	as‐
sociated	with	 increased	 frequency	of	 IgG4
+	memory	B	 cells	 and	 a	
beneficial	shift	in	the	IgG4
+/IgE+	memory	B‐cell	ratio,	reflecting	the	
increased	 IgG4/IgE	 antibody	 fraction	 in	 serum	 and	 resultant	 clini‐
cally	favorable	outcome.	Moreover,	to	our	knowledge,	our	study	is	
the	first	to	demonstrate	increases	in	memory	B	cells	expressing	IgG2 
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or	 IgG4	 following	 allergen	 immunotherapy.	As	 IgG2	 and	 IgG4 have 
anti‐inflammatory	 properties	 and	 are	 induced	 following	 repeated	
antigen‐exposure,41	this	B‐cell	memory	compartment	is	a	potential	
mechanism	by	which	allergen	immunotherapy	modifies	the	natural	
course	of	disease.	In	future	studies,	it	would	therefore	be	of	interest	
to	examine	the	functional	properties	of	allergen‐specific	B	cells,	as	
well	as	the	effector	functions	of	allergen‐specific	IgG	subclasses.67
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